Related Experiment Videos
Induction bleomycin infusion in head and neck cancer
American Journal of Clinical Oncology
|June 1, 1984
Summary
This study investigated bleomycin infusion for head and neck squamous cell carcinoma. While well-tolerated, the bleomycin regimen showed a lower response rate compared to combination therapies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced squamous cell carcinoma of the head and neck presents a significant treatment challenge.
- Induction chemotherapy is a strategy to improve outcomes in these patients.
Purpose of the Study:
- To evaluate the efficacy and toxicity of bleomycin infusion as induction chemotherapy for previously untreated advanced head and neck squamous cell carcinoma.
Main Methods:
- Twenty-one male patients received bleomycin (15 mg/m2 IV bolus followed by 15 mg/m2/day continuous infusion for 7 days).
- Response was assessed after induction, followed by definitive surgery and/or radiation therapy.
- Toxicity was monitored throughout the treatment course.
Main Results:
- A major response rate of 33% (1 complete response, 6 partial responses) was observed.
- The regimen was generally well-tolerated with mild toxicities including fever, alopecia, rash, and mucositis.
- No pulmonary toxicity was detected.
Conclusions:
- Bleomycin infusion as induction chemotherapy for head and neck squamous cell carcinoma is associated with mild toxicity but demonstrates an inferior response rate compared to combination regimens.
- Further research into combination therapies is warranted for improved treatment outcomes.